RT Journal Article
SR Electronic
T1 Antibodies targeting merozoites induce natural killer cell degranulation and interferon gamma secretion and are associated with immunity against malaria
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.14.21267763
DO 10.1101/2021.12.14.21267763
A1 Odera, Dennis O.
A1 Tuju, James
A1 Mwai, Kennedy
A1 Nkumama, Irene N.
A1 Fürle, Kristin
A1 Chege, Timothy
A1 Kimathi, Rinter
A1 Diel, Stefan
A1 Musasia, Fauzia K.
A1 Rosenkranz, Micha
A1 Njuguna, Patricia
A1 Hamaluba, Mainga
A1 Kapulu, Melissa C.
A1 Frank, Roland
A1 Osier, Faith H. A.
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/12/16/2021.12.14.21267763.abstract
AB Natural killer cells are potent immune effectors that can be activated via antibody mediated Fc receptor engagement. Using multiparameter flow cytometry, we found that natural killer (NK) cells degranulate and release IFNγ upon stimulation with antibody-opsonized Plasmodium falciparum merozoites. Antibody-dependent NK activity (Ab-NK) was largely strain-transcending and enhanced the inhibition of invasion into erythrocytes. Ab-NK was associated with the successful control of parasitemia following experimental malaria challenge in African adults. In an independent cohort study in children, Ab-NK increased with age, was boosted by concurrent falciparum infections and associated with a lower risk of clinical episodes of malaria. Nine of 14 vaccine candidates tested induced Ab-NK including some less well-studied antigens - P41, P113, MSP11, RHOPH3, and Pf_11363200. These data highlight an important role for ab-NK in immunity against malaria and provide a new mechanism for the evaluation of vaccine candidatesOne Sentence Summary Antibody-dependent natural killer activation is induced by merozoites and associated with immunity against malariaCompeting Interest StatementThe authors have declared no competing interest.Funding StatementWe are grateful to all the study volunteers who have participated in the CHMI-SIKA study. We are also very grateful to the study teams at the study sites in Kilifi and Ahero, the collaborating teams at Sanaria, the study investigators, and all the clinical and laboratory teams. The CHMI-SIKA study was supported by a Wellcome Trust grant (107499) and sponsored by the University of Oxford. This work was supported by a Sofja Kovalevskaja Award from the Alexander von Humboldt Foundation (3.2 - 1184811 - KEN - SKP) and an EDCTP Senior Fellowship (TMA 2015 SF1001) which is part of the EDCTP2 programme supported by the European Union awarded to F.H.A.O. F.K.M. was supported by a scholarship from the German Academic Exchange Service (DAAD), Funding Programme 57214224, ST-32-PKZ 91608705. This research was commissioned in part by the National Institute for Health Research (NIHR) Global Health Research programme (16/136/33) using UK aid from the UK Government. K.M. was supported by the NIHR Global Health Research Unit Tackling Infections to Benefit Africa (TIBA). The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social CareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The CHMI study was conducted at the KEMRI Wellcome Trust Research Programme in Kilifi, Kenya with ethical approval from the KEMRI Scientific and Ethics Review Unit (KEMRI//SERU/CGMR-C/029/3190) and the University of Oxford Tropical Research Ethics Committee (OxTREC 2-16). All participants gave written informed consent. The study was registered on ClinicalTrials.gov (NCT02739763), conducted based on good clinical practice (GCP), and under the principles of the Declaration of Helsinki. The Junju cohort, were originally recruited in 2005 and has been followed up, for clinical episodes of malaria(Bejon 2006). In this study we used samples collected in 2008. Ethical approval for the Junju study was provided by the Kenyan National and Scientific Ethics Review Committee protocol number 3149. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study protocol and outcomes are published23. Additional original data that support the findings of this study are available from the data governance committee at KWTRP upon reasonable request; dgc@kemri-wellcome.org